Meloxicam 7.5 mg & 15 mg Orodispersible tablet

Meloxicam 7.5 mg & 15 mg Orodispersible tablet

Products
Meloxicam 7.5 mg & 15 mg Orodispersible tablet
Meloxicam 7.5 mg & 15 mg Orodispersible tablet

Information

Meloxicam appears to have better gastrointestinal tolerance than non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) thanks to its preferential inhibition of COX-2 vs. COX-1. The Orodispersible tablets enhance patient compliance, administration without water and accuracy of dosage
All categories
AntibioticsAPIs (Active Pharmaceutical Ingredients)Innovative APIsProducts
Main Categories
APIs (Active Pharmaceutical Ingredients)
ATHENAAthena, a French based MNC, is dedicated to developing life-cycle products, with a broad range of technology platforms for oral delivery with a distinctive focus on modified release formulation as well as oro-dispersible dosage forms. Using these technologies Athena has developed a wide range of products in various therapeutic segments like Pain, CNS, Cardiometabolic, Gastroenterology, Gynaecology and more. Athena Pharmaceutiques has two R&D as well as manufacturing units located in Athena IPS, France and Athena DDS, India. Athena is primarily engaged in a Licensing and Supply business model. We can supply products in Finished form as ODT, Tablet, Capsules, Sachets or Semi-finished form as bulk granules for direct compression and pellets for encapsulation/sachets filing. Athena facilities are approved by EU-GMP, Health Canada, TGA- Australia, ANVISA, RUSSIA, SAPHRA and other countries.

Log in

See all the content and easy-to-use features by logging in or registering!